You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 2.9% | 3.8% |
| Div Cover | 3.2 | 2.6 |
| Op Mrgn | 21.9% | 28.4% |
| ROCE | 61.7% |
| Latest | Forecast | |
|---|---|---|
| P/E | 11.0 | 0.0 |
| PEG | 0.2 | 1.9 |
| Price / Revenue | 2.1 | 2.2 |
| Price / Book value | 6.2 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 18.7% | -0.5% |
| PBT | 56.4% | n/a |
| EPS | 54.3% | 5.2% |
| DPS | -45.0% | 3.3% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | 30,821.00 | 4,800.00 | 119.40p | 15.6 | 2.3 | 7% | 80.00p | 4.3% |
| 2019-12-31 | 33,754.00 | 6,221.00 | 123.90p | 17.9 | 4.8 | 4% | 80.00p | 3.6% |
| 2020-12-31 | 34,099.00 | 6,968.00 | 115.90p | 14.5 | -2.2 | -6% | 80.00p | 4.8% |
| 2021-12-31 | 24,696.00 | 3,599.00 | 90.56p | 22.2 | -1.0 | -22% | 80.00p | 4.0% |
| 2022-12-31 | 29,324.00 | 5,628.00 | 139.70p | 10.3 | 0.2 | 54% | 44.00p | 3.1% |
| GSK's RSV vaccine gets approval in Japan Sharecast News | 25 Sep |
|---|---|
| US FDA approves GSK treatment for myelofibrosis Sharecast News | 18 Sep |
| Japan considering GSK's Nucala drug for sinusitis treatment Sharecast News | 01 Sep |
| GSK RSV vaccine for older adults approved in Japan | 25-Sep-23 14:27 |
|---|---|
| Director/PDMR Shareholding | 21-Sep-23 23:59 |
| Apretude for PrEP receives EMA approval | 19-Sep-23 14:28 |
| FDA approves Ojjaara (momelotinib) | 18-Sep-23 14:26 |
| Director/PDMR Shareholding | 14-Sep-23 00:00 |